Patients
Bleeding
BLEEDING
Of 2769 patients enrolled in the trial, 1948 (at 52 sites in 18 countries) underwent randomization between February 24, 2020, and September 20, 2021; a total of 969 patients were assigned to and 952 received at least 1 biodegradable-polymer sirolimus-eluting stent, whereas 979 were assigned to and 969 received at least 1 durable-polymer zotarolimus-eluting stent (Baseline characteristics and clinical presentation of the trial groups are shown in Table 
Baseline Characteristics and Clinical Presentation

Criteria for High Bleeding Risk
